Liquidia Technologies Inc (LQDA)vsMerck & Company Inc (MRK)
LQDA
Liquidia Technologies Inc
$44.40
-0.20%
HEALTHCARE · Cap: $4.03B
MRK
Merck & Company Inc
$146.72
-0.14%
HEALTHCARE · Cap: $368.89B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 14843% more annual revenue ($67.38B vs $450.91M). LQDA leads profitability with a 30.7% profit margin vs 3.6%. LQDA trades at a lower P/E of 32.4x. LQDA earns a higher WallStSmart Score of 60/100 (C).
LQDA
Buy60
out of 100
Grade: C
MRK
Hold44
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for LQDA.
Margin of Safety
-76.6%
Fair Value
$84.66
Current Price
$146.72
$62.06 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Keeps 31 of every $100 in revenue as profit
Strong operational efficiency at 49.8%
Revenue surging 1843.0% year-over-year
Every $100 of equity generates 28 in profit
Mega-cap, among the largest globally
Strong operational efficiency at 41.2%
Generating 4.5B in free cash flow
Areas to Watch
Premium valuation, high expectations priced in
0.0% earnings growth
Trading at 20.3x book value
Distress zone — elevated risk
Trading at 8.6x book value
4.7% revenue growth
ROE of 7.6% — below average capital efficiency
3.6% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : LQDA
The strongest argument for LQDA centers on Profit Margin, Operating Margin, Revenue Growth. Profitability is solid with margins at 30.7% and operating margin at 49.8%. Revenue growth of 1843.0% demonstrates continued momentum.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bear Case : LQDA
The primary concerns for LQDA are P/E Ratio, EPS Growth, Price/Book.
Bear Case : MRK
The primary concerns for MRK are Price/Book, Revenue Growth, Return on Equity. A P/E of 151.0x leaves little room for execution misses. Thin 3.6% margins leave little buffer for downturns.
Key Dynamics to Monitor
LQDA profiles as a growth stock while MRK is a value play — different risk/reward profiles.
LQDA carries more volatility with a beta of 0.61 — expect wider price swings.
LQDA is growing revenue faster at 1843.0% — sustainability is the question.
MRK generates stronger free cash flow (4.5B), providing more financial flexibility.
Bottom Line
LQDA scores higher overall (60/100 vs 44/100), backed by strong 30.7% margins and 1843.0% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Liquidia Technologies Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and markets various products for the unmet needs of patients in the United States. The company is headquartered in Morrisville, North Carolina.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?